M.I. Boiko, N.S. Radzikhovska

Treatment of sexual dysfunction with phosphodiesterase 5 inhibitors in male multiple sclerosis patients

The objective : To study the effectiveness of phosphodiesterase 5 inhibitors in the treatment of sexual dysfunction in male patients with multiple sclerosis (MS ).

Methods and materials. The study involved 60 male patients with MS. The average age of patients was 32,7 ± 6,8 years. The average duration of disease was 5,2 ± 4,4 years , the degree of disability on a scale EDSS - 3,0 ± 1,0 points (from 1,0 to 6,5 points). Patients underwent clinical - neurological examination with assessment of neurological deficit scale (EDSS) and anonymous testing using questionnaires on the scale to determine the state of sexual function (SF ) (IIEF, SEAR).

Results. Violation of SF was found in 37 (61,7%) men, expressed in decreased desire and arousal, orgasmic dysfunction. Reduced quality of relationships between sexual partners were discovered in 22 (36,7%) MS patients. The improvement of SF in the main group patients after the treatment with phosphodiesterase 5 inhibitors was found, which was statistically significant by all parameters. Improvement of partner relations after the treatment in general and a significant increase of sexual satisfaction quality in relations and overall satisfaction in the relationship.

Conclusions: a significant improvement of sexual function and quality of sexual relations between partners after treatment with inhibitors of phosphodiesterase 5 in male MS patients was discovered. MS patients with SF disorders require the combined treatment.